Type 2 Diabetes Mellitus (T2DM) remains a 
leading contributor to cardiovascular mortality worldwide. 
This study was conducted to investigate the pattern of 
circulating Endothelial Progenitor Cells (EPCs) in T2DM 
patients in comparison with MetS subjects.  
Aim: To investigate the pattern of circulating EMPs in 
T2DM patients in comparison with MetS subjects. 
Methods: The study retrospectively evolved 101 patients 
(54 subjects with T2DM and 47 patients with MetS) and 35 
healthy volunteers. All the patients have given written 
informed consent for participation in the study. The flow 
cytometry was used for predictably distinguishing cell 
subsets, which depend on expression of CD45, CD34, 
CD14, Tie-2, and VEGFR2. Biomarkers were measured at 
baseline of the study. 
Results: There is a significant difference between the 
medians of absolute numbers and frequencies of 
CD14+CD309+ and CD14+CD309+Tie2+ in healthy 
volunteers and patients with dysmetabolic disorders respectively. CD14+CD309+ and CD14+CD309+Tie2+  subsets of circulating EPCs were determined in higher 
concentration among MetS subjects in comparison with 
T2DM patients. Osteoprotegerin (OPG) and hs-C-Reactive 
Protein (CRP), improve significantly predictive model based on T2DM + number of Multiple Cardiovascular 
Risk Factors (MCRFs) >3 for decreased both angiopoetic 
phenotypes of circulating EPCs. Among patient study 
population for category-free NRI, 5% of events (p=0.001) 
and 11% of non-events (p=0.001) were correctly 
reclassified by the addition of hs-CRP and OPG to the base 
model for decreased absolute number of circulating EPCs 
labeled CD14+CD309+. Therefore, 6% of events (p=0.001) 
and 14% of non-events (p=0.002) were correctly 
reclassified using category-free NRI for depleted absolute 
number of circulating EPCs labeled CD14+CD309+Tie2+.  
In conclusion, we suggest that inflammatory biomarkers 
(hs-CRP, OPG) may consider statistically significant 
predictors for decreased EPCs labeled CD14+CD309+ and 
CD14+CD309+Tie2+ among dysmetabolic patients without 
preexisting atherosclerotic lesions of coronary arteries.